Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer

Area of Science:

• Medical Oncology
• Pulmonology
• Cancer Research

Background:

• Small-cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with poor prognosis.
• Treatment options for extensive-stage SCLC (ES-SCLC) have historically been limited.
• Recent advancements have significantly altered the SCLC therapeutic landscape.

Purpose of the Study:

• To synthesize evidence for current SCLC treatment standards.
• To review pivotal clinical trials and international guidelines.
• To provide a comprehensive overview of the evolving SCLC therapeutic landscape.

Main Methods:

• Data synthesized from key clinical trials and network meta-analyses.
• Appraisal of National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines.
• Comprehensive analysis of first-line chemoimmunotherapy regimens for SCLC.

Main Results:

• Concurrent chemoradiotherapy (ccRT) with consolidative immunotherapy is the standard for limited-stage SCLC (LS-SCLC), with prophylactic cranial irradiation (PCI) re-evaluation.
• Immune checkpoint inhibitors (ICIs) combined with platinum-etoposide chemotherapy represent a new standard for ES-SCLC, yielding survival benefits.
• The ADRIATIC trial demonstrated efficacy of consolidative immunotherapy in LS-SCLC.

Conclusions:

• Immunotherapy integration, especially in ES-SCLC, has established new standards and improved patient outcomes.
• Future directions include identifying predictive biomarkers and developing novel therapies like Bi-specific T-cell Engagers (BiTEs) and antibody-drug conjugates.
• Continued research holds promise for further improving the prognosis of SCLC.